Compare Starbucks Corp (SBUX) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Starbucks Corp vs Vertex Pharmaceuticals Incorporated — how do they compare? Starbucks Corp trades at $100.32 (market cap $116.29B), while Vertex Pharmaceuticals Incorporated trades at $522.29 (market cap $134.06B). The key difference: Vertex Pharmaceuticals Incorporated is the larger of the two by market cap, and Starbucks Corp pays a 2.43% dividend while Vertex Pharmaceuticals Incorporated pays none. Which is the better fit depends on your goals.
| SBUX | VRTX | |
|---|---|---|
Market Cap | $116.29B | $134.06B |
Volume | 7,493,833 | — |
Sector | Consumer Cyclical | Health |
52-Week High | $108.55 | $557.96 |
52-Week Low | $78.46 | $376.62 |
Enterprise Value | $135.12B | $128.18B |
Dividend Yield | 2.43% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Starbucks (SBUX) trades at $102.01, down 2.35% today, with a bearish technical signal but strong recent earnings beats. Revenue grew to $37.18B in 2025, though net income margin compressed to 5.17%. The stock faces headwinds from high valuation multiples (P/E 58.97) and negative shareholder equity, but analyst consensus remains positive with a $113.60 price target. Recent news highlights CEO Niccol's turnaround progress and record sales from seasonal offerings.
Outlook is mixed: operational improvements and debt reduction support upside, but margin pressure and union disputes pose risks. The stock offers growth potential if execution continues, yet investors must weigh high valuation against competitive and labor challenges in the coffee retail sector.
Vertex Pharmaceuticals (VRTX) trades at $528.9, down 3.15% on the day, amid a mixed technical and fundamental backdrop. The stock shows a bullish moving average signal but neutral oscillators, with key support at $522. Fundamentally, 2025 revenue reached $12.0B with a strong net income margin of 35%, though recent quarterly EPS results have been mixed. The company recently completed the acquisition of Crinetics Pharmaceuticals, signaling growth ambitions.
The outlook remains positive given analyst consensus favoring a Buy rating (84%) and a $548.78 price target, implying upside. Key opportunities include revenue growth from new drug launches, while risks involve competitive pressures and earnings volatility. The stock's current valuation at a P/E of 30.8 requires sustained execution to justify further gains.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Starbucks Corp
Starbucks Corporation retails, roasts, and provides its own brand of specialty coffee. The Company operates retail locations worldwide and sells whole bean coffees through its sales group, direct response business, supermarkets, and on the world wide web. Starbucks also produces and sells bottled coffee drinks and a line of ice creams.
Read more on SBUX →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
